Entera Bio Ltd.NASDAQ: ENTX

Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints

· Issued by Entera Bio Ltd.

On 6ix: 6ix.com/news/entera-bio-announces-excellent-topline-phase-2-bmd-data-for-eb613-the-study-met-its-primary-and-key-secondary-endpoints

Watch Entera Bio's latest callEntera Bio (NASDAQ:ENTX) Q1 2022 Earnings Call · Replay · May 18, 2022Read the transcript of Entera Bio (NASDAQ:ENTX) Q1 2022 Earnings Call
  • Subjects receiving the 2.5 mg dose of EB613 showed significant dose-related increases in BMD at the lumbar spine, total hip, and femoral neck at 6 months
  • Subjects receiving the 2.5 mg dose of EB613 for 6 months had a significant placebo adjusted increase of 3.78% in lumbar spine BMD (p

Entera Bio Ltd. on 6ix

Earlier from Entera Bio

Later from Entera Bio

All Entera Bio news releases